What are the most important questions I should ask my oncologist about Bladder Cancer?How of often does s2 high...

Critical Questions for Your Bladder Cancer Care + Bleeding Patterns

I'll address both your questions systematically, using evidence-based guidance tailored to your specific situation.

---

PART 1: MOST IMPORTANT QUESTIONS TO ASK YOUR ONCOLOGIST

Based on the NCCN Guidelines for Bladder Cancer and guidance from cancer advocacy organizations, here are the priority questions organized by category:

DIAGNOSTIC & STAGING QUESTIONS

These questions help you understand your specific disease:

1. "What is the exact stage and grade of my tumor based on the pathology report?"

• Why ask: You need to know the TNM staging (T stage, N stage, M stage) and grade (1, 2, or 3)
• What to listen for: Specific pathology findings like:
  • Depth of invasion (Ta, T1, T2a, T2b, T3, T4)
  • Grade (1 = low-grade, 2 = intermediate, 3 = high-grade)
  • Presence of carcinoma in situ (CIS)
  • Lymphovascular invasion
  • Margin status (was tumor completely removed?)

2. "Was my tumor papillary or sessile in appearance, and what does that mean for my prognosis?"

• Why ask: Morphology affects prognosis and treatment
• Papillary = better prognosis, lower invasion risk
• Sessile = worse prognosis, higher invasion risk

3. "Did the pathology show any high-risk features like carcinoma in situ (CIS), lymphovascular invasion, or inadequate resection margins?"

• Why ask: These findings change treatment intensity
• CIS presence = requires more aggressive intravesical therapy (BCG, not just chemotherapy)
• Inadequate margins = repeat TURBT needed

4. "What is my risk of recurrence and progression based on my specific findings?"

• Why ask: Helps you understand surveillance intensity needed
• Low-grade Ta: ~5-10% progression to muscle-invasive over 5 years
• Low-grade T1: ~10-15% progression over 5 years
• High-grade T1: ~30-40% progression over 5 years

5. "Do I need any additional imaging (CT urogram, MRI, PET scan) to rule out upper tract disease or metastases?"

• Why ask: Staging completeness affects treatment planning
• Your lack of hydronephrosis is favorable, but imaging confirmation is standard

---

TREATMENT PLANNING QUESTIONS

These questions help you understand your treatment options:

6. "What is the goal of my treatment — cure, remission, or symptom control?"

• Why ask: Frames realistic expectations
• For non-muscle-invasive disease: Goal is typically cure with TURBT + intravesical therapy
• For muscle-invasive disease: Goal is cure with chemotherapy + cystectomy (if fit)

7. "What are ALL my treatment options, including standard and non-standard approaches?"

• Why ask: Ensures you're aware of the full spectrum
• For non-muscle-invasive: TURBT, intravesical chemotherapy, intravesical BCG, repeat TURBT
• For muscle-invasive: Neoadjuvant chemotherapy, radical cystectomy, bladder-preserving approaches, clinical trials
• Ask specifically: "Are there clinical trials available for my stage?"

8. "If I have non-muscle-invasive disease, will I need intravesical chemotherapy or BCG, and what's the difference?"

• Why ask: These have different side effect profiles and efficacy
• Intravesical chemotherapy (mitomycin C, gemcitabine):
  • Single dose or 6-week course
  • Lower toxicity
  • Better for low-grade disease
  • Typical for your likely presentation
• BCG (Bacillus Calmette-Guérin):
  • More intensive (6-week induction, possible maintenance)
  • Higher toxicity (flu-like symptoms, dysuria)
  • Better for high-grade disease or CIS
  • Reserved for higher-risk patients

9. "If I have muscle-invasive disease, what is the role of neoadjuvant chemotherapy, and am I a candidate?"

• Why ask: Neoadjuvant chemotherapy improves survival in muscle-invasive disease
• Your non-smoker status and good health make you a good candidate if needed
• Typical regimen: Cisplatin-based chemotherapy (MVAC or gemcitabine-cisplatin) for 3-4 cycles before surgery

10. "What are the side effects I should expect from my recommended treatment, both short-term and long-term?"

• Why ask: Helps you prepare and manage expectations
• Intravesical chemotherapy: Local irritation, dysuria, frequency, hematuria (usually mild)
• BCG: More severe irritative symptoms, systemic symptoms, risk of BCG infection (rare)
• Chemotherapy: Nausea, fatigue, neuropathy, kidney function changes
• Cystectomy: Permanent urinary diversion, sexual dysfunction, bowel changes

---

MONITORING & SURVEILLANCE QUESTIONS

These questions help you understand follow-up care:

11. "How often will I need cystoscopy and imaging surveillance, and for how long?"

• Why ask: Surveillance intensity depends on stage/grade
• Low-grade non-muscle-invasive: Cystoscopy every 3-6 months for 2 years, then annually
• High-grade non-muscle-invasive: More frequent (every 3 months)
• Post-cystectomy: Imaging surveillance for metastases

12. "What symptoms should I watch for between appointments, and when should I call you?"

• Why ask: Early detection of recurrence improves outcomes
• Red flags: Hematuria, irritative symptoms, flank pain, constitutional symptoms
• Get specific contact information for urgent concerns

13. "Will I need repeat TURBT, and if so, when and why?"

• Why ask: Repeat TURBT at 4-6 weeks is standard for T1 disease
• Purpose: Ensure complete tumor resection, upstage if muscle invasion found
• Your likely scenario: Probably yes, given your T1 risk

14. "How will we monitor for treatment response and disease progression?"

• Why ask: Understand what "success" looks like
• Methods: Cystoscopy findings, imaging (CT, MRI), urine cytology, biomarkers
• Ask: "What specific markers or findings indicate my treatment is working?"

---

PRECISION MEDICINE & BIOMARKER QUESTIONS

Based on the CancerPatientLab webinar "Self-Advocacy in the Era of Precision Medicine" by Rome Madison, these questions help you access advanced testing:

15. "What is driving my tumor growth — do I have any actionable mutations or biomarkers?"

• Why ask: Identifies potential targeted therapy options
• Relevant for bladder cancer: FGFR mutations, PD-L1 expression, MSI-H/dMMR status
• Your scenario: Less likely to have actionable mutations in low-grade disease, but worth checking

16. "Should I get comprehensive genomic profiling (CGP) of my tumor?"

• Why ask: May identify clinical trial opportunities or targeted therapies
• Especially important if: You have high-grade disease, muscle-invasive disease, or recurrent disease
• Ask: "Can you send my tumor tissue for comprehensive genomic profiling?"

17. "Are there any liquid biopsy tests (blood tests) that could help monitor my disease?"

• Why ask: Emerging technology for early detection of recurrence
• Bladder cancer-specific: Circulating tumor DNA (ctDNA) testing
• Potential benefit: Earlier detection of recurrence before imaging shows disease

18. "Are there any clinical trials available for my specific stage and grade?"

• Why ask: Access to cutting-edge treatments
• Ask specifically: "How will you help me find clinical trials, and are there trials at other institutions I should consider?"